Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 85

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 85
---
 know-how, and the transfer of manufacturing or manufacturing rights of such products, technologies
or know-how outside of Israel, without the prior approval of the IIA. Therefore, the discretionary approval of an IIA committee would
be required for any transfer or license to third parties inside or outside of Israel of know-how or for the transfer outside of Israel
of manufacturing or manufacturing rights related to those aspects of such technologies. We may not receive those approvals. Furthermore,
the IIA may impose certain conditions on any arrangement under which it permits us to transfer technology or development.

The transfer or license of
IIA-supported technology or know-how outside of Israel and the transfer of manufacturing of IIA-supported products, technology or know-how
outside of Israel may involve the payment of significant amounts, depending upon the value of the transferred or licensed technology or
know-how, our research and development expenses, the amount of IIA support, the time of completion of the IIA-supported research project
and other factors. These restrictions and requirements for payment may impair our ability to sell, license or otherwise transfer our technology
assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product or technology
outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of Israel
of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts that we are
required to pay to the IIA. The terms and conditions of the IIA grants may require that a company which ceases the development of know-how,
technology or products using IIA grants not due to a failure of such development activities, be required to repay such amount of grants,
which in our case, amount to $2.6 million (including interest at the amount of $0.3 million).

We may not be able to enforce covenants not-to-compete under current Israeli law that might result in added competition for our products.

We have non-competition agreements
with all of our employees, all of which are governed by Israeli law. These agreements prohibit our employees from competing with or working
for our competitors, generally during their employment and for up to 12 months after termination of their employment. However, Israeli
courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all, to enforce those provisions for relatively
brief periods of time in restricted geographical areas, and only when the employee has obtained unique value to the employer